Histone post-translational modifications associated to BAALC expression in leukemic cells

Biochemical and Biophysical Research Communications

Volumn 417, Issue 2, 2012, Pages 721-725

  Franzoni, Alessandra ^a,b   Passon, Nadia ^a,b   Fabbro, Dora ^a   Tiribelli, Mario ^c   Damiani, Daniela ^c   Damante, Giuseppe ^a,b  

^a Istituto di Genetica Medica   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c Clinica Ematologica   (Italy)

Author keywords

BAALC; Chromatin immunoprecipitation; Epigenetics; Histone acetylation; Histone methylation; Leukemia

Indexed keywords

BAALC PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING;

CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84855845417     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.013     Document Type: Article

References (18)

1. Mrózek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev. 2004, 18:115-136.
2. Gregory T.K., Wald D., Chen Y., Vermaat J.M., Xiong Y., Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J. Hematol. Oncol. 2009, 2:23.
3. Baldus C.D., Tanner S.M., Ruppert A.S., Whitman S.P., Archer K.J., Marcucci G., Caligiur I.M.A., Carroll A.J., Vardiman J.W., Powell B.L., Allen S.L., Moore J.O., Larson R.A., Kolitz J.E., de la Chapelle A., Bloomfield C.D. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003, 102:1613-1618.
4. Langer C., Radmacher M.D., Ruppert A.S., Whitman S.P., Paschka P., Mrózek K., Baldus C.D., Vukosavljevic T., Liu C.G., Ross M.E., Powell B.L., de la Chapelle A., Kolitz J.E., Larson R.A., Marcucci G., Bloomfield C.D. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111:5371-5379. Cancer and Leukemia Group B (CALGB).
5. Santamaría C., Chillón M.C., García-Sanz R., Pérez C., Caballero M.D., Mateos MV., Ramos F., de Coca A.G., Alonso J.M., Giraldo P., Bernal T., Queizán J.A., Rodríguez J.N., Puig N., Balanzategui A., Sarasquete M.E., Alcoceba M., Díaz-Mediavilla J., San Miguel J., González M. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann. Hematol. 2010, 89:453-458.
6. Tanner S.M., Austin J.L., Leone G., Rush L.J., Plass C., Heinonen K., Mrózek K., Sill H., Knuutila S., Kolitz J.E., Archer K.J., Caligiuri M.A., Bloomfield C.D., De La Chapelle A. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc. Natl. Acad. Sci. USA 2001, 98:13901-13906.
7. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128:707-719.
8. Lennartsson A., Ekwall K. Histone modification patterns and epigenetic codes. Biochim. Biophys. Acta 2009, 1790:863-868.
9. Verdone L., Caserta M., Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem. Cell Biol. 2005, 83:344-353.
10. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 2006, 75:243-269.
11. Margueron R., Trojer P., Reinberg D. The key to development: interpreting the histone code?. Curr. Opin. Genet. Dev. 2005, 15:163-176.
12. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., Fry B., Meissner A., Wernig M., Plath K., Jaenisch R., Wagschal A., Feil R., Schreiber S.L., Lander E.S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
13. Mikkelsen T.S., Ku M., Jaffe D.B., Issac B., Lieberman E., Giannoukos G., Alvarez P., Brockman W., Kim T.K., Koche R.P., Lee W., Mendenhall E., O'Donovan A., Presser A., Russ C., Xie X., Meissner A., Wernig M., Jaenisch R., Nusbaum C., Lander E.S., Bernstein B.E. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007, 448:553-560.
14. Webb C.F., Bryant J., Popowski M., Allred L., Kim D., Harriss J., Schmidt C., Miner C.A., Rose K., Cheng H.L., Griffin C., Tucker P.W. The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development. Mol. Cell. Biol. 2011, 31:1041-1053.
15. Gaboli M., Kotsi P.A., Gurrieri C., Cattoretti G., Ronchetti S., Cordon-Cardo C., Broxmeyer H.E., Hromas R., Pandolfi P.P. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev. 2001, 15:1625-1630.
16. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van Putten W., Skrabanek L., Campagne F., Mazumdar M., Greally J.M., Valk P.J., Löwenberg B., Delwel R., Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
17. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174:1619-1628.
18. Manuyakorn A., Paulus R., Farrell J., Dawson N.A., Tze S., Cheung-Lau G., Hines O.J., Reber H., Seligson D.B., Horvath S., Kurdistani S.K., Guha C., Dawson D.W. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J. Clin. Oncol. 2010, 28:1358-1365.